Pherecydes Pharma changes its Corporate Governance and appoints Didier Hoch as CEO and Chairman of its first Board of Directors

– FRANCE, Nantes –  Pherecydes Pharma (EPA: ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, today announced the appointment of previous Chairman of its Supervisory Board Didier Hoch as Chairman of the Board of Directors and CEO, effective on May 19, 2022, alongside previous members of the Supervisory Board who were appointed as the first directors of Pherecydes Pharma.

These appointments are concurrent with shareholders’ approval of the change in the Corporate Governance by adopting a Board of Directors and a General Management, where the Board of Directors is thus composed of 7 members, 2 of whom are independent.

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied to several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines. Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector, and academic research.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.